Introduction {#S1}
============

Tumor necrosis factor α (TNFα) is an essential signaling protein in the innate and adaptive immune systems. It also plays an important role in tissue degeneration and repair ([@B1]). It is now recognized that the expression of TNF receptor 2 (TNFR2) is more limited than that of TNF receptor 1 (TNFR1). In addition, new evidence suggests that the sTNF-mediated signaling pathway *via* TNFR1 drives a predominantly pro-inflammatory program whereas mTNF binding to TNFR2 primarily initiates immune modulation and tissue regeneration. These findings suggest that we may selectively target TNFR1 and TNFR2 for therapeutic purposes, providing promise for the context-specific treatment of autoimmune diseases. This review is provided to summarize TNFα and TNFR expression, structure, and signaling pathways, to discuss TNFR1/TNFR2 signaling in autoimmune diseases especially concerning their correlation with Tregs and organ regeneration, as well as to propose treatment strategies aimed at TNFR1/TNFR2 in autoimmune diseases.

The Basic Biology of TNFα and TNFR {#S2}
==================================

Expression, Structure, and Function of TNFα {#S2-1}
-------------------------------------------

Tumor necrosis factor α plays a vital role in many physiological and pathological conditions. First, TNFα is essential for the regulation of embryonic development, the sleep--wake cycle, lymph node follicle, and germinal center formation. Second, TNFα not only promotes the production of inflammatory cytokines but also enhances the adhesion and permeability of endothelial cells and promotes the recruitment of immune cells such as neutrophils, monocytes, and lymphocytes to sites of inflammation ([@B2], [@B3]). These actions help to mediate both acute and chronic systematic inflammatory reactions under conditions of infection or autoimmunity. In addition, TNFα also causes cell apoptosis and necrosis under specific conditions. Furthermore, high levels of TNFα can also result in cachexia and endotoxin-induced septic shock ([@B4]). It has also been identified as an endogenous pyrogen.

Tumor necrosis factor α is primarily generated by macrophages and monocytes. However, other cells such as some subsets of T cells, NK-cells, dendritic cells, B cells, cardiomyocytes, fibroblasts, and astrocytes are also the producers of this cytokine at a low level ([@B5], [@B6]).

Tumor necrosis factor α is a type II transmembrane protein. It exists as a membrane-bound form (mTNFα) with relative molecular weight 26 kDa primarily. mTNFα can be processed into 17 kDa soluble TNFα (sTNFα) through the action of the matrix metalloproteinase known as TNFα converting enzyme (TACE: ADAM17) ([@B7], [@B8]). In addition, mTNFα also has the ability to process external signals as a receptor ([@B9]). sTNFα circulates throughout the body and confers TNFα with its potent endocrine function, far away from the site of its synthesis. Both sTNFα and mTNFα are active as non-covalently bonded homotrimers.

While bacterial lipopolysaccharide (LPS) serves as a major stimulant of the innate immune system, microbial antigens, enterotoxins, and cytokines including TNFα itself are also able to trigger TNFα production. TNFα also stimulates the generation of numerous pro-inflammatory cytokines including IL-6, IL-8, TNFα itself, adhesive molecules, chemokines, and metalloproteinases ([@B10], [@B11]), potentially leading to a TNFα-mediated pro-inflammatory autocrine loop ([@B12]). On the other hand, TNFα can boost the synthesis of anti-inflammatory factors such as IL-10 and corticosteroids, to limit the inflammatory cytokines secretion. As a whole, TNFα initiates a rapid and vigorous immune reaction, thus limiting the extent and duration of inflammation when the invasion has been resolved ([@B13]). Furthermore, serving as a co-stimulator, TNFα enhances the reactions of neutrophils, monocytes, and lymphocytes for defense against microbes.

Expression, Structure, and Signaling Pathways of TNFR {#S2-2}
-----------------------------------------------------

Tumor necrosis factor α exerts its function *via* two different type I transmembrane receptors, TNFR1 and TNFR2. Each has a characteristic extracellular domain, a transmembrane segment, and intracellular domain. The extracellular domains of both receptors have similar a cysteine-rich motif that is repeated two to six times, are active as homodimers but intriguingly do not form TNFR1/TNFR2 heterodimers ([@B14]). Nevertheless, the intracellular segments of TNFR1 and TNFR2 do not bear homologous sequences and activate distinct signaling pathways ([@B15]).

Both TNFR1 and TNFR2 membrane receptors also can be converted into soluble forms (sTNFR1 and sTNFR2) through the activity of TACE enzymes. Both TNFRs can interact with either mTNFα or sTNFα. TNFR1 is ubiquitously expressed on nearly all cells in the body and can be activated by both mTNFα and sTNFα. TNFR2, conversely, is restricted to thymic T lymphocytes, endothelial cells, microglia, and oligodendrocytes ([@B16]), and can only be fully initiated by mTNFα. Once mTNFα binds to TNFR2, the combination is too stable to dissociate ([@B17]). This is not the case for sTNFα which induces weak signaling and exhibits a low affinity for TNFR2 ([@B18]). Other salient features of TNFR2 are that cellular activation status highly regulates its expression and unlike TNFR1, it does not contain a cytoplasmic death domain.

It is well accepted that TNFα binding to TNFR1 activates two different intricate signal pathways: the maintenance of cell survival and the promotion of inflammatory cytokine expression; cell apoptosis and necrosis. The balance between these two pathways hinges upon many factors such as cell type, cell activation status, an intracellular or extracellular microenvironment, recruitment of adaptor molecules, the concentration of complex inhibitors of apoptosis proteins (cIAP), or the level of NF-κB expression ([@B19]). When TNFα binds to TNFR1, the intracellular domains interact with TNFR type 1-associated death domain protein (TRADD), which recruits receptor interacting protein-1 (RIP-1) and TNF receptor-associated factor-2 (TRAF-2) to form Signal complex I ([@B5]) (Figure [1](#F1){ref-type="fig"}). Signal complex I can trigger NF-κB, which launches the transcriptions of many different genes including those associated with cell survival, production of inflammatory cytokines, and antiapoptotic gene pathways. Signal complex I is also able to activate extracellular signal-regulated kinases, the stress-activated MAP kinases p38, and c-Jun N-terminal kinase (JNK), which are important for AP-1, the important promoter of inflammation and proliferation, and other transcription factors through MAPK3 signaling pathways ([@B20]--[@B22]).

![When mTNF/TNF receptor 2 (TNFR2) is activated, the intracellular domains recruit existing cytoplasmic TNF receptor-associated factor-2 (TRAF-2)--cIAP-1--cIAP-2 complexes resulting in the initiation of both canonical and non-canonical NF-κB/Rel and MAPK pathways activation. NF-κB/Rel and MAPK pathways activate IL-2 promoter and trigger IL-2 expression. NF-κB pathways also transcript genes associated with cell survival and cell proliferation. So, mTNF/TNFR2 signaling can enhance expansion and stability of Tregs and increase Treg sensitivity to low level of IL-2. It also activates the reciprocal PI3K/Akt pathway. Activation of Akt signaling impairs Th17 differentiation, correlated with an increased phosphorylation of STAT5 ([@B143]). When soluble TNFα (sTNFα)/TNFR1 is activated, the intracellular domains interact with TRADD, which receptor interacting protein-1 (RIP-1) and TRAF-2 to form Signal complex I, then further triggering extracellular signal-regulated kinases (ERKs), p38, and c-Jun N-terminal kinase (JNK). The mechanisms of TNFR1 on Th17 differentiation are still unclear. These transcription factors might phosphorylate STAT3, upregulate the level of ROR-γt, and increase IL-17 production.](fimmu-09-00784-g001){#F1}

Signal complex I formation is temporary and rapidly dissociates from TNFR1, mediating the binding of the Fas-associated death domain protein (FADD) to form Signal complex II which coordinates downstream signaling of the caspase cascade ([@B23]). When the kinase activities of RIP-1 and RIP-3 inhibit apoptosis signaling, necrosis is activated ([@B24]).

Recently, several studies have demonstrated that TNFR2 promotes a remarkable degree of cell activation, migration, and proliferation ([@B24]). When TNFα binds to TNFR2, the intracellular domains recruit existing cytoplasmic TRAF-2--cIAP-1--cIAP-2 complexes ([@B25]) (Figure [1](#F1){ref-type="fig"}). cIAP can exert ubiquitin-ligase activity and can inhibit caspases and other apoptosis-inducing factors ([@B5]), resulting in the initiation of both canonical and non-canonical NF-κB activation ([@B25]--[@B27]). The interaction of TNFα with TNFR2 also activates the reciprocal PI3K/Akt pathway. This pathway not only maintains survival and enhances proliferation ([@B28], [@B29]) but also recruits Etk and forms the TNFR2--Etk--VEGFR2 (vascular endothelial growth factor receptor 2) complex which participates in cell adhesion, migration, survival, and proliferation ([@B30], [@B31]).

Although TNFR2 triggers NF-κB in a slower manner than TNFR1, TRFR1 maintains a longer duration of NF-κB activity ([@B25]). Even though TNFR2 lacks a death domain, caspase activation and cell apoptosis can be initiated under conditions of stress or when the cIAP pool exhausted *via* interaction of intracellular domains with Signal complex II. Other theories suppose that TNFR2 activation exhausts the cIAP pool, which facilitates a shift of TNFR2 signaling to FADD, triggering the apoptosis pathway.

The Function of TNFR1 and TNFR2 on Autoimmune Diseases {#S3}
======================================================

Disease models using transgenic mice have broadened our horizons concerning the importance of pathogens in triggering or shaping autoimmunity. Compared with wild-type mice, TNFα^−/−^ mice exhibit an enhanced susceptibility to pathogen invasion ([@B2]). They also exhibit a deficiency in TNFR1 ([@B32]). It is noteworthy that mice expressing non-cleavable TNF (which cannot be processed into sTNF) have a diminished capacity to resist pathogens ([@B33], [@B34]). This demonstrates that many of the pro-inflammatory functions of sTNF are indeed mediated by TNFR1 signaling, while mTNF (predominantly *via* TNFR2) can at least partly provide the immune system with some pathogen protection.

Overexpression of TNF results in a severe chronic inflammatory arthritis in collagen-induced arthritis (CIA) mice, an animal model of rheumatoid arthritis (RA). When the TNFR1 gene is knockout, these arthritic effects are largely diminished, whereas TNFR2 deficiency exacerbates disease ([@B35], [@B36]). Interestingly, the use of TNF inhibitors dramatically improves symptoms in a manner reminiscent of TNFR1 deficiency ([@B36], [@B37]). In addition, central nervous system-specific overexpression of TNF in transgenic mice also resulted in a spontaneous severe demyelination ([@B38]). These results confirm the pro-inflammatory role of TNFR1, while leaving the door open for an immune-modulatory role of TNFR2. In the experimental autoimmune encephalomyelitis (EAE) mouse model, TNF knockout delayed disease onset, however, once established, the symptoms were more serious in knockouts than in wild-type mice ([@B39]). This raises the suggestion that TNF is essential to the promotion of a potent immune response *via* TNFR1. However, once the immune response is triggered, the absence of TNF may result in the failure to expand and activate Tregs *via* TNFR2 which in turn results in tissue and organ damage. Increasing evidence indicates that TNFR2 plays a vital role in the modulation of the immune system, most likely through its interactions with Tregs.

It has been well studied that polymorphisms in the TNFR2 gene have a strong correlation with a wide variety of autoimmune diseases, e.g., RA ([@B40]--[@B42]), Crohn's disease ([@B43]), systemic lupus erythematosus ([@B44]), ankylosing spondylitis (AS) ([@B45]), inflammatory bowel diseases (IBD) ([@B46]), and ulcerative colitis and scleroderma ([@B47]). The consequence of this polymorphism is to hamper TNF binding to TNFR2, which subsequently limits the activation of NF-κB ([@B48]), and most likely hampers TNFR2 signaling pathway in Tregs.

TNFR2's Relationship with Tissue Regeneration and Tregs {#S4}
=======================================================

The Relationship Between TNFR2 and Tissue Regeneration {#S4-1}
------------------------------------------------------

TNF receptor 2 provides a critical contribution to neural survival and regeneration. In the mouse model of retinal ischemia, TNFR2 showed a protective function by activating the Akt signaling pathway ([@B49]). The cuprizone-induced demyelination and remyelination mouse model gave similar results. In this model, TNF or TNFR2 knockout led to delayed remyelination and a decreased proliferation and maturation of oligodendrocyte progenitors. These findings provide support for the notion that TNF/TNFR2 serves as principal players in oligodendrocyte regeneration ([@B50]). A tissue regenerative role for the TNFR2 signaling pathway has also been described in several other disorders ([@B51]). Several other studies have also indicated that TNFR2 agonists are active in pancreatic regeneration, cardioprotection, remyelination, and survival of some neuron subtypes and also in stem cell proliferation ([@B51]--[@B54]).

The Relationship Between TNFR2 and Tregs {#S4-2}
----------------------------------------

The interplay between inflammatory and regulatory pathways orchestrates an effective immune response that provides protection from pathogens while limiting injury to host tissue. Tregs are prototypical immunosuppressive cells that dampen excessive immune responses and maintain immune homeostasis by inhibiting effector T cell proliferation and cytokine production which prevents the development of autoimmune diseases and tissue destruction ([@B55]--[@B58]). Regulatory T cells can mediate their suppressive function either by secreting cytokines like IL-10, TGF-β, or IL-35 or by direct cell--cell contact ([@B59], [@B60]). These cells can act by suppressing the effector T cells directly at the target site ([@B61]), by suppressing DC in the regional lymph nodes and thereby preventing priming of T cells in the regional lymph nodes ([@B62]), or by recruiting mast cells to the site ([@B63]). Mice deficient in Foxp3^+^ T cells develop fatal autoimmune disease ([@B64]), and continuous expression of Foxp3 throughout life prevents autoimmunity ([@B65]). Recent studies have contradictorily demonstrated that TNF upregulates or downregulates the expansion and function of Tregs *via* TNFR2.

One specific study has demonstrated that as with human Tregs, both thymic and peripheral murine CD4^+^CD25^+^ Tregs expressed remarkably high levels of TNFR2 relative to CD4^+^CD25^−^ effector T cells ([@B66]). By contrast, TNFR1 was barely detectable.

When responding to TCR stimulation, TNFR2 expression on Tregs is further increased relative to activated effector T cells ([@B67]). In TNFR2 knockout mice, although the numbers and function of Tregs are comparable with wild-type mice, these Tregs failed to expand when stimulated under inflammatory conditions either *in vivo* or *in vitro*. This suggests that under non-inflammatory conditions, TNF is not required for thymic Tregs to maintain immune homeostasis ([@B67], [@B68]). Conversely, TNFR2 can mediate the activation of anergic Tregs in response to TCR stimulation ([@B67]), having profound effects on their stabilization ([@B69]), proliferation ([@B70]), and function ([@B71]).

Interestingly, one study about type 1 diabetes model on NOD mice found that TNFR1 deficiency protected the mice from diabetes and showed mild peri-insulitis. The absence of TNF--TNFR1 signaling increased the number and function of Tregs both *in vitro* and *in vivo* ([@B72]). They proposed that the primed effector T cells secreting TNF that signals through TNFR2, which is constitutively expressed at a high level on Tregs ([@B67]), leads to expansion of Tregs. We also considered the TNFR1 deficiency is consequential to elevated TNFR2 signaling on Tregs, as a result of increased ligand availability as opposed to a loss of stimulatory TNFR1 signaling. As a consequence, increased Tregs prevent effector T cells migrating into islets. Similar work has been exhibited in EAE model ([@B73]).

We and other investigators have reported that IL-2 is essential for the development and maintenance of Foxp3^+^ Treg cells ([@B56], [@B57]). Neutralization of circulating IL-2 elicits autoimmune gastritis in BALB/c mice and triggers early onset of diabetes by inhibiting physiological proliferation of peripheral CD4^+^CD25^+^ cells, but not CD4^+^CD25^−^ cells ([@B74]). Interestingly, TNF can enhance this effect markedly both in human and mice ([@B67], [@B75]). In mice, it exerts the effect markedly in a time-dependent and dose-dependent manner ([@B67]). The initial exposure to TNF transiently abrogates Treg suppressive functions, whereas longer exposures restore their suppressive activity. This means that short-term stimulation of TNF mimics the early phases of the inflammatory reaction, thus allowing effector T cells to escape from the inhibition mediated by Tregs, presumably favoring elimination of the pathogens. However, long-term exposure to TNF may facilitate the activation and expansion of Tregs, restoring their suppressive capabilities, thus limiting excessive inflammation.

Recently, one investigation showed that anti-TNF antibody, adalimumab expanded the pool of Tregs and maintained their function *via* mTNF/TNFR2 both *in vitro* and *in vivo*. Moreover, upregulation of Foxp3 by adalimumab was reliant upon low levels of IL-2 production and subsequently STAT5 activation of Tregs ([@B76]). They proposed that TNFR2 is able to increase the sensitivity of IL-2 signaling, thereby amplifying the impact of small changes in IL-2 production ([@B77]). Coincidentally, another study demonstrated that IL-2 transcription was directly triggered by TNFR2. It showed that CD4^+^ T cell intrinsic tmTNF/TNFR2, but not sTNF/TNFR1, promotes Il2 promoter activity and IL-2 mRNA stability in a Foxp3-independent manner both *in vitro* and *in vivo*. When tmTNF/TNFR2 signaling is blocked or impaired, IL-2 production is reduced, and the Th17 differentiation elevated, which was associated with increased STAT3 activity and ROR-γt level, decreased STAT5 activity, while, it can be prevented by adding exogenous IL-2 ([@B78]). However, whether TNFR2 regulates IL-2 expression in a Foxp3-independent manner or a Foxp3-dependent manner, whether IL-2 can in turn regulate TNFR2 expression, the precise signaling pathways by which TNFR2 regulates IL-2 expression still remain important areas for future studies (Figure [2](#F2){ref-type="fig"}).

![When the TNF receptor 2 (TNFR2) signaling pathway is activated, it increases Tregs stability, responses to TCR stimulation, expansion, and function. It enhances Tregs and effector T cells to produce IL-2 and promotes the sensitivity of Tregs to IL-2. IL-2 can inhibit Th17 cells differentiation and the effect of TNFR2 signaling on Tregs. Under inflammatory condition, mTNFR2 can shed to sTNFR2, sTNFR2 neutralizes TNF and hampers IL-6 expression.](fimmu-09-00784-g002){#F2}

Work in the last decade has established that the subset of Foxp3^+^ Tregs expressing TNFR2 showed increased suppressive function relative to those that did not express TNFR2. However, these studies suggested that Foxp3 expression may not be the only factor to confer Treg suppressive capacity ([@B79]). Indeed, TNFR2 may be needed as a unique activator to maximize their suppressive activity ([@B67], [@B79]). Furthermore, when TNFR2^−/−^ mice are used in the colitis model, some studies have found that nTregs require TNFα *via* TNFR2 as a critical factor for optimizing Treg suppressive function under inflammatory conditions whereas iTregs are fully suppressive without TNF signaling ([@B79]). Therefore, it is likely that anti-TNFα therapy for different human autoimmune diseases may have dichotomous effects on the function of nTregs versus iTregs. Whether or not this has any influence on disease expression would depend on whether nTregs or iTregs play the predominant regulatory role in that specific disease. Diseases in which iTregs are functionally predominant would encourage the anti-inflammatory effects of anti-TNFα therapy, with no deleterious effects on iTregs and a favorable response. By contrast, diseases in which nTregs functionally predominate, anti-TNFα therapy might result in a loss of Treg function. This dichotomy offers a novel mechanistic paradigm for the enigma of variable responses to anti-TNF-α therapy in different human diseases.

It is well accepted that Tregs consist of two major identified subtypes: natural or thymic Tregs (nTregs/pTregs), developed in the thymus; induced Tregs or peripheral Tregs (iTregs/pTregs) generated in the periphery from CD4^+^CD25^−^ T cells (pTregs) or iTregs induced with anti-CD3/CD28 coated beads, IL-2 and TGF-β from naive CD4^+^ T cells *in vitro* (iTregs) ([@B80]--[@B82]). The two populations have subtle difference, such as methylation status of conserved non-coding sequence 2 \[known as the Treg cell-specific demethylated region (TSDR) in the Foxp3 locus\]. Although the stability of Tregs is still controversial, most researchers generally recognized that nTregs are predominantly more stable and long-lived than iTregs because TSDR in nTregs but not iTregs is hypomethylated, which is great important for Foxp3 stability ([@B83], [@B84]). While, a small percentage of nTregs may become unstable, losing Foxp3 expression and transforming to effector T cells, such as Th1, Th17 cells under some pathogenic conditions. As stated earlier, the suppressive function of Foxp3^+^ Tregs expressing TNFR2 was superior to those that did not express TNFR2 ([@B79]). Okubo et al. found one method for Tregs expansion *ex vivo* using a synthetic TNFR2 agonist which produces Tregs with 14 homogenous cell-surface markers ([@B85]). Although it still needs more researches to definite this issue, the relationship between TNF--TNFR2 and nTregs provides a promising way to apply Tregs to autoimmune therapy. Even if some researchers insisted that iTregs induced by IL-2 and TGF-β is less stable, we and others found these iTregs are more stable and resistant to phenotypic plasticity in some autoimmune diseases and acute graft-versus-host disease ([@B58], [@B86]--[@B90]). Furthermore, our laboratory recently found that TNF (*via* TNFR2) enhanced the differentiation and suppressive function of iTregs induced *in vitro* (unpublished observation). As such, therapeutic intervention with these iTregs *via* TNFR2 has become a promising strategy for the treatment of autoimmune disorders ([@B91]).

Intriguingly, van Mierlo et al. described that CD4^+^CD25^+^ Treg cells were able to shed higher amounts of TNFR2 for a longer period of time than CD4^+^CD25^−^ T cells. In addition, WT Tregs can suppress IL-6 production when LPS was injected into mice. By contrast, TNFR2-deficient Tregs failed to do this but maintained their suppressive function *in vitro* ([@B92]). Thus, shedding of TNFR2 might represent yet another novel mechanism for Tregs to inhibit the pro-inflammatory action of TNF at inflammatory sites. It was presumed that low concentrations of TNFR2, through receptor shedding or other processes, might possibly decrease the concentration of TNF and prevent it from binding to inflammatory cells ([@B93], [@B94]). Unfortunately, this concept highlights a discrepancy. If CD4^+^CD25^+^ Tregs shed enough of their TNFR2, TNF will fail to have any effects on Treg activation, expansion, or function.

Despite this question, some laboratories have offered conflicting results concerning the effect of TNF on human Tregs. They believe that TNF stimulation directly hampers the suppressive capacity of human CD4^+^CD25^high^ Tregs both *in vitro* and *ex vivo* ([@B71], [@B95]--[@B98]). Moreover, the inhibitory effects of TNF are more apparent under coculture conditions than they are under pretreatment condition ([@B99]). This discrepancy may be due to the cross-species differences between murine and human T cells. It also raises the possibility of differences in the sensitivity of the experimental conditions or the differing methodologies employed in each laboratory. Valencia et al. showed that CD4^+^CD25^high^ Tregs stimulated with high levels of TNF and IL-2 lost their immune suppressive capabilities, presumably these findings were as a result of only the early stages of TNF stimulation ([@B95]).

Indeed, these studies also showed that neutralization of TNF might actually restore Treg suppressive ability and maintain the survival of Tregs in patients with RA and IBD ([@B95], [@B98], [@B100], [@B101]). In neonatal NOD mice, treatment with TNF promoted the development of diabetes accompanied with a reduced number and impaired function of Tregs instead ([@B102]). By contrast, administration of TNF to young adult NOD mice also ameliorated diabetes but enhanced the proliferation of Tregs ([@B102]) instead. We hypothesized that the NOD mouse is a spontaneous animal model of T1DM. The severity of inflammation is deteriorating with age in NOD mice, and the immune microenvironment is changing, which may impact the density of TNFR1 and TNFR2 on the surface of Tregs, the sensitivity to TNF, even the TNF form tending to sTNF or mTNF, and the activation of TNFR1 or TNFR2 signaling pathways. Nonetheless, the precise effect of TNF on Tregs activity remains elusive, and it still needs more in-depth investigations.

Targeting sTNF/TNFR1 in Autoimmune Diseases {#S5}
===========================================

Treatment with TNF inhibitors has been a successful strategy for several diseases such as RA, IBD, psoriasis, and cancer-related cachexia. Recent anti-TNF therapies are all aimed at directly binding the ligand to TNF. Five anti-TNF drugs are currently approved for the therapy of human autoimmune disorders: RA, plaque psoriasis, psoriatic arthritis, AS, and IBD. Trade names for these drugs include infliximab, adalimumab, certolizumab pegol, golimumab, and etanercept ([@B103]--[@B107]). Notably, it raises a novel mechanism that adalimumab prefers binding to mTNF on monocytes and increased their mTNF expression, followed by enhancement of Treg TNFR2 expression and its binding to mTNF. As a consequence, adalimumab expanded functional Tregs equipped to suppress Th17 cells ([@B76]).

Despite the wide use of TNF inhibitors, drawbacks include severe side effects like opportunistic infections, reactivation of tuberculosis, and even development of autoimmune diseases, lymphoma, and many other cancers ([@B108]--[@B111]). In addition, some patients do not respond well to these anti-TNF treatments ([@B105], [@B106]). Furthermore, in clinical trials on MS patients, treatment with TNF inhibitors resulted in disease exacerbation ([@B112], [@B113]).

Because sTNF/TNFR1 may play a role in promoting inflammation, and because mTNF/TNFR2 can result in immune modulation and tissue regeneration, new therapeutics selectively targeting sTNF/TNFR1 have emerged. Both TNFR1-selective antagonists and sTNF-special antagonists may leave the mTNF/TNFR2 signaling pathway intact, which may minimize or diminish the detrimental effects caused by TNF inhibitors. This provides protective TNF-mediated responses such as neural regeneration, survival, and immune modulation without promoting inflammation. Indeed, mTNF alone may be enough to form TNF-dependent secondary lymphoid organ structure and granulomas ([@B114], [@B115]), and to partially provide resistance to pathogens ([@B116], [@B117]), without causing any autoimmune diseases ([@B114], [@B116]).

sTNF-Selective Dominant-Negative TNF (dnTNF) Derivatives {#S5-1}
--------------------------------------------------------

A novel type of TNF inhibitor called signaling-incompetent dnTNF derivatives was described in 2005 ([@B118]). This TNF mutein can rapidly and specifically inactivate sTNF through interaction with endogenous sTNF, followed by formation of mixed TNF heterotrimers, leaving mTNF unaffected. XPro1595, an improved version of this mutein, exhibited a profound ameliorating effect on EAE and inflammatory arthritis. XPro1595-treated animals were also less susceptible to infection ([@B119], [@B120]). In addition, relative to etanercept, XPro1595 treatment significantly delayed onset and more efficiently ameliorated EAE symptoms ([@B121]), even when applied at the disease peak period ([@B122]). Interestingly, XPro1595 administration increased the level of TNFR2 expression in the lesion area, illustrating that mTNF signaling *via* TNFR2 may indeed play a role in neural regeneration ([@B123]).

TNFR1-Selective Antagonistic TNF {#S5-2}
--------------------------------

Some investigators have identified R1antTNF, a TNFR1-selective antagonistic mutant TNF from a phage display library ([@B124]). The affinity of R1antTNF to TNFR1 is comparable to that of the human wild-type TNF, and it does not interfere with TNFR2-mediated bioactivity. In two acute hepatitis models, R1antTNF significantly ameliorated liver injury as demonstrated by reduced serum levels of alanine aminotransferase and pro-inflammatory cytokines. This therapeutic effect of R1antTNF had an advantage over that of current TNF inhibitors ([@B125]). PEG-R1antTNF, another TNFR1-selective antagonistic mutant TNF, remarkably decreased morbidity, ameliorated disease symptoms, and improved demyelination in EAE mouse model. Furthermore, it significantly suppressed Th1 and Th17 cell activation and infiltration in the spinal cord ([@B126]).

TNFR1-Specific Antibodies {#S5-3}
-------------------------

Recently, one study compared the therapeutic effects of the TNFR1-specific antibody, DMS5540 with that of etanercept in the CIA model. Both reagents comparably suppressed disease progression. One difference noted was that etanercept administration increased effector T-cell activity, specifically in joints undergoing remission. This was not observed in mice treated with DMS5540 ([@B127]). These findings suggest that the immune regulatory function of TNFR2 is masked by traditional TNF inhibitors, like etanercept. It proves the hypothesis that selective targeting of TNFR1 not only inhibits autoimmune responses but also enhances Treg activity, making it a better choice for TNF therapy over standard TNF inhibitors ([@B127]).

Targeting TNFR2 in Autoimmune Diseases {#S6}
======================================

It remains to be verified whether selective inhibition of sTNF/TNFR1 proves enough to redirect the available TNF to TNFR2 for improving immune regulation and tissue regeneration. In support of this, mTNF/TNFR1 plays a role in neuron cell survival in under certain circumstances ([@B128]). On the other hand, sTNF probably activates TNFR2 in high TNFR2-expressing cells such as Tregs ([@B128]). It still remains to be determined whether mTNF signaling *via* TNFR2 is enough to activate Tregs and if additional activation of sTNF *via* TNFR2 can promote Treg activity. Most importantly, it is likely to have a narrow range of safe and effective dose since TNFR1 is expressed ubiquitously almost all types of cells throughout the body. Thus, selective TNFR2 agonists can provide yet another tissue-specific or cell-specific therapy for autoimmune disorders.

TNF receptor 2 agonists were engineered using point mutation ([@B129]). Treatment with these TNFR2 agonists has been successfully used for cancer therapy and also for research in immunology ([@B130]). As mentioned earlier, mTNF binds much greater affinity to TNFR2 than to sTNF itself ([@B130]). The investigators undertaking this line of research also found another small synthetic molecule that acted as trimer ligands which were similar to TNFR2 ([@B131]). Over time, additional literature indicates that TNF and TNFR2 agonists exert a tremendous effect on heart regeneration, bone marrow stem cells, and even neuron regeneration in murine models of Parkinson's disease ([@B132]--[@B134]).

TL1A-Ig, a natural TNF-receptor superfamily member agonist is used as a novel method for the *in vivo* expansion of Tregs ([@B135]). Okubo et al. found another method for Treg expansion *ex vivo* using a synthetic TNFR2 agonist which produces Tregs with 14 homogenous cell surface markers ([@B85]). This method provides an optimal way to obtain sufficient quantities of Tregs use in autoimmune therapy.

TNF Inducers {#S6-1}
------------

One well-known TNF inducer is the mycobacterium bacillus Calmette--Guerin (BCG) vaccine. Another one is the BCG equivalent, complete Freund adjuvant. Although BCG induction of TNF can interact with both TNFR1 and TNFR2, it may induce TNF production at low levels, thereby possibly boosting the expansion of Tregs ([@B85]), which can provide benefits for the treatment of autoimmune diseases. Newly synthesized TNF inducers improve the specificity for the TNFR2 receptor and may hold the promise for the treatment of type 1 diabetes ([@B136]).

CD3-Specific Antibodies {#S6-2}
-----------------------

As a distinctive cell-surface marker of T cells, CD3 antagonists are targeted to be mainly applied as immunosuppressive agents to protect against organ transplant rejection. While a CD3-specific antibody generally seen as an immunosuppressive agent, it may promote TNF generation and TNFR2 expression ([@B137]), and thus exert the similar effects as the TNFR2 agonist.

It is particularly noteworthy that the safety profile of TNFR2 agonists has not been well defined. Not all of TNFR2 agonists exert their effects using the same mechanism. Some can function as agonists while some TNFR2 antibodies can be antagonists and still others may induce anergy. It is clear that many different factors come into play concerning the activation and regulation of the balance between TNFR1 versus TNFR2 signaling. These subtle differences in TNF stimulation can result in the generation of divergent intracellular signaling pathways ([@B138]). More studies with these new agents are needed to determine if their use results in any changes in TNF signaling and what effects these changes have on physiological consequences.

To avoid the systemic toxicity, injection of TNFR2 agonists directly into sites of inflammation or lymphoid organs might be a promising approach. Their local application would be attractive for diseases such as autoimmune Sjogren's syndrome or skin diseases because the skin is an easily accessible organ that is amenable to agonist delivery at desired concentrations, thus reducing systemic toxicity. However, not all lesions are as accessible. Pancreatic injection might potentially trigger pancreatitis.

In spite of their non-specificity, several alternative strategies are also in progresses which act *via* immune modulation of TNFR2 signaling pathways. However, high concentrations of TNFR2 agonists could potentially overwhelm TNFR2 signaling and might shift their activities to the pro-apoptotic pathway *via* TNFR1. This would result in apoptosis of both autoreactive and bystander cells. In spite of their lower relative toxicity to TNFR1 agonists, TNFR2 agonists might still have some degree of toxicity, particularly toward CNS cells ([@B139]). Overexpression of TNFR2 in a transgenic mouse model resulted in systemic toxicity ([@B140]) and also elicited several autoimmune diseases as mentioned earlier ([@B141]). It is noteworthy that one specific TNFR2 agonist enhanced thymocyte proliferation *in vitro* and *in vivo*, caused a febrile reaction and a transient inflammatory reaction ([@B142]). Thus, the potential toxicity of TNFR2 agonist therapy still needs to be investigated carefully.

Conclusion {#S7}
==========

Taken together, as with anti-cytokine or immunosuppressive drug therapies which must be used continuously to keep steady blood concentration, any of the absolute TNF inhibitors, sTNF inhibitors, TNFR1 antagonists, or TNFR2 agonists, could potentially be given at a low dose discontinuously and intermittently. However, sTNF/TNFR1-special antagonists can specifically block TNFR1 signaling pathway and leave the protective effect, e.g., neural regeneration and immune modulation *via* TNFR2. Furthermore, TNFR2-special agonists avoid the detrimental effects initiated by total TNF inhibitors and sTNF/TNFR1-special antagonists due to their limited tissue expression. sTNF inhibitors, TNFR1 antagonists, and TNFR2 agonists, when used alone or in combination therapy, may provide a superior therapeutic strategy for the treatment of various autoimmune and degenerative diseases.
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